Our commitment to neuroscience
Neuroscience is advancing at an unprecedented rate, and we are proud to be at the forefront of this transformation. Our focus is on helping children and adults suffering from debilitating and degenerative neurological disorders. Our long‐term commitment to advancing neuroscience and toxins research is evidenced by 30 years of clinical experience.
Neuroscience is central to Ipsen’s internal innovation and external partnering, integral to the company’s overall strategy, and a key driver of long‐term value and growth.
OUR COMMITMENT TO PATIENTS
Since 1994, Ipsen has focused on pioneering research in neurotoxins. People suffering from neurological disorders need treatments, and we’ve become a global leader in creating them.
We have accomplished this through the research, development, manufacturing and commercialization of neurotoxins to help treat certain types of spasticity in adults and children two years and older. Such disorders include cervical dystonia, cerebral palsy, hemifacial spasm and blepharospasm.
Additionally, our work in neurotoxins extends to aesthetic indications with our partner Galderma, including the reduction of glabellar lines (frown lines).
We also remain focused on bringing medicines to patients where there is high unmet need and we will continue to collaborate where there are opportunities to bring promising new treatments to patients.
A unique educational program
Over 800 experienced physicians benefited from Ipsen’s toxin educational program, the only one in the world with published findings.
Our expertise in neuroscience
Since 1994, Ipsen has focused on pioneering research in neurotoxins. People suffering from neurological disorders need treatments, and we’ve become a global leader in creating them through the research, development, manufacturing and commercialization of neurotoxins to help treat certain types of spasticity in adults and children two years and older, cervical dystonia, cerebral palsy, hemifacial spasm, and blepharospasm. Additionally, our work in neurotoxins extends to aesthetic indications with our partner Galderma, including the reduction of glabellar lines (frown lines).
Assessing the benefits of early intervention in post-stroke care
With over 12 million people a year experiencing a stroke globally and over 100 million living with the effects and consequences of stroke, the burden of stroke is high and set to increase.
Rising to the challenge, life after stroke
Globally, stroke is the 2nd leading cause of death worldwide, in addition to being the 3rd leading cause of combined death and disability across the world, with approximately 1 in 4 people over the age of 25 expected to experience…
Improving post-stroke care for survivors across the globe
Stroke is the 2nd leading cause of death worldwide, in addition to being the 3rd leading cause of combined death and disability, with approximately 1 in 4 people over the age of 25 expected to experience a stroke at some point in their lives.
Making clinical trials relevant to stroke survivors
At Ipsen, we endeavor for all our clinical trials to be reflective of the real world, and this requires the participation of a cross-section of people living with a particular condition. However, for some stroke survivors with post-stroke spasticity –…
Gathering insights to improve clinical trials direction study patient advisory board
At Ipsen, we strive to improve the experiences of those participating in our clinical trials and do this by capturing insights from people living with the conditions we are investigating to help us to improve how we run our studies.
Unchartered territory: Mapping the cervical dystonia patient experience
We collaborated with Dystonia Europe to help uncover the unmet needs of people living with cervical dystonia – a rare, underdiagnosed neurological movement disorder that primarily affects the muscles in the neck. This can cause the head to turn to…
Why we must work together to improve life after stroke
At Ipsen, we are committed to helping people who are navigating the challenges of living with debilitating neurological conditions. This is why today, as we mark the start of the European Congress for Neurorehabilitation (ECNR) in Lyon, I want to…
The Ixcellence Network®: celebrating 10 years of progress in improving the standard of care for patients living with debilitating neurological disorders
Continuing medical education is vital to maintaining the quality of clinical practice, which in turn can improve patient outcomes. As a pioneer in botulinum neurotoxin type A (BoNT-A) treatment, Ipsen has worked with a scientific steering committee of international experts…
Ipsen neuroscience clinical trials
We are constantly striving to bring new treatments to the clinical trial stage to meet patients’ unmet medical needs.
Learn moreWHAT’S IN THE PIPELINE FOR IPSEN NEUROSCIENCE
As the only company with recombinant botulinum neurotoxins in our portfolio and in active clinical development, our R&D centers around the world are pioneering research in neuroscience. Recombinant toxins, with longer duration of action in preclinical models, could potentially give healthcare providers the ability to choose the most appropriate neurotoxin for their patients.
Recognizing the need for new, longer-lasting treatment options, Ipsen has leveraged its knowledge and more than 30 years’ experience with native botulinum neurotoxins and R&D capabilities to harness the power and potential of toxin biology and to pioneer innovation in toxin therapy.
In addition to our expertise in neurotoxins, our strategy includes research into rare neurodegenerative disorders. Our strong development capabilities cover all stages of the drug development process, and we have a successful track record of global regulatory approvals and accelerated pathways, making Ipsen an ideal partner for neuroscience innovation.